KromaTiD’s Dark Lab Files: Under the CAR Hood
The design and manufacture of chimeric antigen receptor (CAR) T cells is fraught with complex hurdles. Some of these are encountered during production while others [...]
The design and manufacture of chimeric antigen receptor (CAR) T cells is fraught with complex hurdles. Some of these are encountered during production while others [...]
The pace at which autologous CAR-T cells can be manufactured has been an obstacle for this very powerful technology from the start. Producing a cutting-edge [...]
Chimeric antigen receptor (CAR) T cells have tremendous promise for treatment of cancer and other conditions. Multiple CAR-T therapies have attained FDA approval in the [...]
Pancreatic Ductal Adenocarcinoma (PDAC) represents greater than 90% of pancreatic cancer cases [1,2]. Early symptoms are relatively non-specific, with critical early treatment sometimes delayed after [...]
Cellular adoptive immunotherapies, such as CAR-T cells, are among the most effective tools in modern medicine’s toolbox for fighting cancer, yet tumor cells are nothing [...]
Multiple hurdles face developers of novel cell-based therapies, such as CAR-T, to successfully produce effective therapeutics. Following is a brief summary of some of the key [...]
A variety of DNA modification tools are relied upon for advanced gene and cell therapies (i.e. CAR-T cells) to continue to progress. These include [...]
Autologous CAR-T cell therapy is a type of adoptive cell therapy in which T-cells from a patient’s own immune system are modified in a laboratory [...]